| Alternative title | Novelty of Canadian manufacture nasopharyngeal swabs for collection of samples being tested for SARS-CoV-2 in a pandemic setting |
|---|
| Download | |
|---|
| DOI | Resolve DOI: https://doi.org/10.3389/fpubh.2024.1344295 |
|---|
| Author | Search for: Palomino-Padilla, Sandra; Search for: Caceres-Cardenas, Guillermo; Search for: Calderon, Rodrigo; Search for: Ko, Alex C-T.1; Search for: Garnett, Lauren; Search for: Doan, Kaylie; Search for: Chong, Patrick; Search for: Lino, Hammerly; Search for: Caceres, Tatiana; Search for: Veres, Teodor1ORCID identifier: https://orcid.org/0000-0002-9594-8042; Search for: Dos Santos, Claudia C.; Search for: Nielsen, Birgit1; Search for: Ugarte-Gil, Cesar |
|---|
| Affiliation | - National Research Council of Canada. Medical Devices
|
|---|
| Funder | Search for: National Research Council of Canada. Industrial Research Assistance Program |
|---|
| Format | Text, Article |
|---|
| Subject | swabs; nasopharyngeal; RT-PCR; SARS-CoV-2; COVID-19 |
|---|
| Abstract | Objectives: The COVID-19 pandemic caused a global shortage of nasopharyngeal (NP) swabs, required for RT-PCR testing. Canadian manufacturers were contacted to share NP swab innovations. The primary objective was to determine whether novel NP test swabs were comparable to commercially available swabs regarding user characteristics, ability to collect a specimen, and diagnostic performance using RT-PCR testing.
Methods: Participants were randomized by swab (test/control) and nostril (left/right). A calculated positive percent agreement ≥90% was considered successful. Mean Ct values of viral genes and housekeeping gene (RNase P) were considered similar if a Ct difference ≤ 2 between control and test group was obtained. There also was a qualitative assessment of swabs usability.
Results: 647 participants were enrolled from Huaycan Hospital in Lima, Peru, distributed over 8 NP swabs brands. Seven brands agreed to share their results. There were no statistically significant differences between the test swabs of these 7 brands and control swabs.
Conclusion: All the seven brands are comparable to the commercially available flocked swabs used for SARS-CoV-2 regarding test results agreement, ability to collect a specimen, and user characteristics. |
|---|
| Publication date | 2024-05-09 |
|---|
| Publisher | Frontiers |
|---|
| Licence | |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | b15c8660-352d-4f98-9dbd-8f9edd722945 |
|---|
| Record created | 2025-06-12 |
|---|
| Record modified | 2025-06-12 |
|---|
